Autus Valve Continued Access Study (CAS)
← catalyst calendarNCT07466745 · readout in 437 d
Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
36estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-27 | actual | When the study began enrolling |
| Primary completion | 2027-10-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Congenital Heart Disease
Intervention
- Device: Pulmonary Valve Replacement Surgery
Primary outcomes
what the primary-completion date above is the date OFPrimary Safety Endpoint
measured 30 Days post-valve implantation
Primary Effectiveness Endpoint
measured 6 Months post-valve implantation
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed